What is crizotinib?
Crizotinib is targeted chemotherapy suitable for cancer treatment in people who express anaplastic lymphoma kinase (ALK). This enzyme promotes tumor growth, allowing cancer to develop and spread. Since 2011, Crizotinib has been still in clinical trials, but a number of study results suggest promising results in the treatment and treatment of some cancers. This medicine is part of a drug class that treats cancer by attacking specific cancers and provides targeted therapy into rogue cells with minimal damage to adjacent cells. In the short term, this stops the tumor growth, as the cells cannot continue replication without an enzyme. In the long run, tumors begin to decrease in patients to Crizotinib therapy and cancer does not spread to other areas of the body. The drug can be effective in the treatment of anaplastic lymphoma with large cells, neuroblastoma and non -masotic lung cancer.
Target therapy is only effective in patients who carry a goal. There are two ways to find out if the summer will beTo use the patient cancer. The first is a genetic test that seeks a goal to see if the patient's body bears a sensitive gene. The second is to try targeted therapy and determine whether the patient's cancer is reacting. The best approach depends on the patient, therapy and cancer. The physician will discuss the possibilities during the process of developing the treatment plan so that the patient can decide informedly.
This medicine can be used by mouth, which makes it easier to use patients because they do not have to go to an infusion clinic for cancer treatment. It can be combined with other therapies for cancer treatment, including surgery and radiation to remove tumors and destroy as many cancer cells as possible. As with other cancer treatment, Crizotinib can have more effects including fatigue, nausea, vomiting and anemia. The doctor will monitor the patient this medicine for signs of complications and distress. If the drug is poorly tolerated, there may be options for managing side effects so that the patient can complete therapy.
When drugs are in clinical trials, patients have access to these experiments if they meet the ability to compete. Patients who want to try Crizotinib can discuss it with their doctors to see if they are good candidates. The physician can provide information about open clinical trials and help patients with the process of applying and registration. Instructions for clinical evaluation are very strict and not all applicants will meet the standards.